Drugs / REGN21353
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07850921 | Jun 2027 → Jul 2031 expected | prostate carcinoma | Regeneron Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN21353 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07850921 ↗ |